- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01049633
B-Lymphocyte Immunotherapy in Islet Transplantation for Initial Islet Graft Failure
June 9, 2014 updated by: National Institute of Allergy and Infectious Diseases (NIAID)
B-Lymphocyte Immunotherapy in Islet Transplantation: Single Subject Modification to Calcineurin-Inhibitor Based Immunosuppression for Initial Islet Graft (CIT-0501)
Type 1 diabetes is an autoimmune disease in which the insulin-producing pancreatic beta cells are destroyed, resulting in poor blood sugar control.
The purpose of this study is to determine the safety and effectiveness of islet transplantation, combined with immunosuppressive medications and medications to support islet survival for treating type 1 diabetes in individuals experiencing hypoglycemia unawareness and severe hypoglycemic episodes.
Study Overview
Status
No longer available
Conditions
Intervention / Treatment
- Biological: Allogeneic Pancreatic Islet Cells
- Drug: Sirolimus
- Biological: Basiliximab
- Drug: Tacrolimus
- Drug: Antibacterial, Antifungal, and Antiviral Prophylaxis
- Drug: Trimethoprim/sulfamethoxazole
- Drug: Clotrimazole
- Drug: Valganciclovir
- Drug: Heparin
- Drug: Enoxaparin
- Drug: Pentoxifylline
- Drug: Aspirin
Detailed Description
Type 1 diabetes is commonly treated with the administration of insulin, either by multiple insulin injections or by a continuous supply of insulin through a wearable pump.
Insulin therapy allows long-term survival in individuals with type 1 diabetes; however, it does not guarantee constant normal blood sugar control.
Because of this, long-term type 1 diabetic survivors often develop vascular complications, such as diabetic retinopathy, an eye disease that can cause poor vision and blindness, and diabetic nephropathy, a kidney disease that can lead to kidney failure.
Some individuals with type 1 diabetes develop hypoglycemia unawareness, a life-threatening condition that is not easily treatable with medication and is characterized by reduced or absent warning signals for hypoglycemia.
For such individuals, pancreas or pancreatic islet transplantation are possible treatment options.
Insulin independence among islet transplant recipients tends to decline over time.
New strategies aimed at promoting engraftment of transplanted islets are needed to improve the clinical outcomes associated with this procedure.
Study Type
Expanded Access
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Hospital of the University of Pennsylvania
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Enrolled in clinical trial DAIT CIT-05 (NCT00468442)
- Islet graft failure: absent stimulated C-peptide (<0.3ng/mL) in response to mixed meal tolerance test
Exclusion Criteria:
- Untreated proliferative diabetic retinopathy
- Blood Pressure: systolic blood pressure>160mmHg or diastolic blood pressure>100mmHg
- Measured glomerular filtration rate (GFR) using iohexol < 80ml/min/1.73m^2 Strict vegetarians with a calculated GFR < 70ml/min/1.73m^2
- Presence or history of macroalbuminuria > 300mg/g of creatinine
- Presence or history of panel-reactive anti-HLA antibodies above background by flow cytometry
- For female participants: Positive Pregnancy Test, presently breast-feeding, or unwillingness to use effective contraceptive measures for the duration of the study and 3 months after discontinuation. For male participants: intent to procreate during the duration of the study or within 3 months after discontinuation or unwillingness to use effective measures of contraception. Oral contraceptives, Norplant, Depo-Provera and barrier devices with spermicide are acceptable contraceptive methods; condoms used alone are not acceptable.
- Active infection including hepatitis B, hepatitis C, HIV, or TB as determined by a positive skin test or clinical presentation, or under treatment for suspected TB. Positive tests are acceptable only if associated with a history of previous vaccination in the absence of any sign of active infection. Positive tests are otherwise not acceptable, even in the absence of any active infection at the time of evaluation.
- Negative screen for Epstein-Barr Virus (EBV) by IgG determination
- Invasive aspergillus, histoplasmosis, or coccidiomycosis infection within one year prior to study enrollment
- Any history of malignancy except for completely resected squamous or basal cell carcinoma of the skin
- Known active alcohol or substance abuse
- Anemia (Hgb < 11 g/dL),neutropenia (<1,500/µL), or thrombocytopenia (platelets <100,000/µL)
- A history of Factor V deficiency
- Any coagulopathy or medical condition requiring long-term anticoagulant therapy (e.g., warfarin) after transplantation (low-dose aspirin treatment is allowed) or patients with an International Normalized Ratio (INR) >1.5
Severe co-existing cardiac disease, characterized by any one of these conditions:
- recent myocardial infarction (within past 6 months)
- evidence of ischemia on functional cardiac exam within the last year
- left ventricular ejection fraction <30%
- Persistent elevation of liver function tests (LFTs) at the time of study entry (e.g., persistent SGOT (AST), SGPT (ALT), Alk Phos or total bilirubin, with values >1.5 times normal upper limits
- Symptomatic cholecystolithiasis
- Acute or chronic pancreatitis
- Symptomatic peptic ulcer disease
- Severe unremitting diarrhea, vomiting or other gastrointestinal disorders potentially interfering with the ability to absorb oral medications
- Hyperlipidemia despite medical therapy (fasting LDL cholesterol > 130 mg/dL, treated or untreated; and/or fasting triglycerides > 200 mg/dL)
- Receiving treatment for a medical condition requiring chronic use of systemic steroids, except for the use of ≤ 5 mg prednisone daily, or an equivalent dose of hydrocortisone, for physiological replacement only
- Use of any investigational agents within 4 weeks of enrollment
- Administration of live attenuated vaccine(s) within 2 months of enrollment
- Any medical condition that, in the opinion of the investigator, will interfere with the safe completion of the trial, such as chronic central neurologic disease
- Treatment with any anti-diabetic medication other than insulin within 4 weeks of enrollment
- A previous pancreas transplant, unless the graft failed within the first week due to thrombosis, followed by pancreatectomy and the transplant occurred more that 6 months prior to enrollment
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Registration Dates
First Submitted
January 12, 2010
First Submitted That Met QC Criteria
January 12, 2010
First Posted (Estimate)
January 14, 2010
Study Record Updates
Last Update Posted (Estimate)
June 11, 2014
Last Update Submitted That Met QC Criteria
June 9, 2014
Last Verified
June 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Glucose Metabolism Disorders
- Metabolic Diseases
- Immune System Diseases
- Autoimmune Diseases
- Endocrine System Diseases
- Diabetes Mellitus
- Diabetes Mellitus, Type 1
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Vasodilator Agents
- Anti-Infective Agents, Local
- Anti-Infective Agents
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Fibrinolytic Agents
- Fibrin Modulating Agents
- Platelet Aggregation Inhibitors
- Cyclooxygenase Inhibitors
- Antipyretics
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Protective Agents
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 Enzyme Inhibitors
- Antibiotics, Antineoplastic
- Hormone Antagonists
- Anticoagulants
- Steroid Synthesis Inhibitors
- Antiprotozoal Agents
- Antiparasitic Agents
- Antioxidants
- Phosphodiesterase Inhibitors
- Free Radical Scavengers
- Antimalarials
- Folic Acid Antagonists
- 14-alpha Demethylase Inhibitors
- Cytochrome P-450 CYP2C9 Inhibitors
- Radiation-Protective Agents
- Calcineurin Inhibitors
- Anti-Dyskinesia Agents
- Anti-Infective Agents, Urinary
- Renal Agents
- Cytochrome P-450 CYP2C8 Inhibitors
- Aspirin
- Heparin
- Anti-Bacterial Agents
- Enoxaparin
- Antifungal Agents
- Clotrimazole
- Miconazole
- Tacrolimus
- Valganciclovir
- Sirolimus
- Basiliximab
- Trimethoprim
- Sulfamethoxazole
- Antiviral Agents
- Pentoxifylline
Other Study ID Numbers
- DAIT CIT-0501
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 1 Diabetes Mellitus
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
AstraZenecaCompletedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
University of California, San FranciscoJuvenile Diabetes Research FoundationCompletedType 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMUnited States, Australia
-
Capillary Biomedical, Inc.TerminatedType 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMAustria
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)CompletedType 1 Diabetes Mellitus | T1DM | T1D | New-onset Type 1 Diabetes MellitusUnited States, Australia
-
Shanghai Changzheng HospitalRecruitingBrittle Type 1 Diabetes MellitusChina
-
Capillary Biomedical, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Insulin-Dependent, 1Australia
-
Spiden AGDCB Research AGRecruitingType 1 Diabetes Mellitus | Type 1 Diabetes Mellitus With Hypoglycemia | Type 1 Diabetes Mellitus With HyperglycemiaSwitzerland
-
Instytut Diabetologii Sp. z o.o.National Center for Research and Development, Poland; Nalecz Institute of Biocybernetics...UnknownType 1 Diabetes Mellitus With Hyperglycemia | Type 1 Diabetes Mellitus With HypoglycaemiaPoland
Clinical Trials on Allogeneic Pancreatic Islet Cells
-
Frantisek SaudekRecruitingIslets of Langerhans TransplantationCzechia
-
National Center for Research Resources (NCRR)UnknownDiabetes Mellitus
-
Midhat H. AbdulredaDiabetes Research Institute Foundation; Bascom Palmer Eye InstituteRecruiting
-
University Hospital, GrenobleAlfediamCompletedType 1 Diabetes MellitusFrance, Switzerland
-
University Hospital, GrenobleTerminatedType 1 Diabetes MellitusFrance, Switzerland
-
NovocellCHRISTUS Health; Diabetes & Glandular Disease Research Associates, P.A., San...TerminatedDiabetes Mellitus, Type 1United States
-
University of VirginiaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Wyeth...UnknownDiabetes Mellitus, Type 1United States
-
University Hospital, GrenobleCompletedDiabetes Mellitus, Type 1France, Switzerland
-
University Hospital, Basel, SwitzerlandRecruitingType 1 Diabetes MellitusSwitzerland
-
Ospedale San RaffaeleMinistry of Health, ItalyCompleted